Home Newsfeeds Societe Generale Downgrades Koninklijke Philips to Hold

Societe Generale Downgrades Koninklijke Philips to Hold

Societe Generale analyst Delphine Lee downgrades Koninklijke Philips (NYSE:PHG) from Buy to Hold.

byBenzinga Newsdesk

July 25, 2022

1 minute read

Societe Generale analyst Delphine Lee downgrades Koninklijke Philips (NYSE:PHG) from Buy to Hold.

Morgan Stanley Maintains Overweight on Axonics, Raises Price Target to $80

By Benzinga Newsdesk

August 2, 8:28 AM

Morgan Stanley analyst Cecilia Furlong maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $73 to $80.

AXNX

Nike Likely To Report Lower Q4 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

June 29, 6:14 AM

NIKE, Inc. (NYSE: NKE) is expected to report its fourth quarter fiscal 2023 financial results after the closing bell on June 29, 2023.

NKE

B of A Securities Upgrades Cardinal Health to Neutral, Raises Price Target to $80

By Benzinga Newsdesk

November 4, 2:50 PM

B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:CAH) from Underperform to Neutral and raises the price target from $64 to $80.

CAH

Wave Life Sciences’ Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases

By Vandana Singh

May 23, 9:22 AM

Wave Life Sciences Ltd (NASDAQ: WVE) announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and

WVE

Societe Generale Downgrades Koninklijke Philips to Hold

Related Posts

Morgan Stanley Maintains Overweight on Axonics, Raises Price Target to $80

Nike Likely To Report Lower Q4 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

B of A Securities Upgrades Cardinal Health to Neutral, Raises Price Target to $80

Wave Life Sciences’ Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases